Drugs / VIP236
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05712889 | Jan 2023 → Oct 2024 | neoplasm | Vincerx Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIP236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05712889 ↗ |
| Route | Intravenous | “VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.” NCT05712889 ↗ |